- Home
- SABR vs KURA Comparison
SABR vs KURA Comparison
Compare SABR & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | KURA |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.3M | 841.6M |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SABR | KURA |
|---|---|---|
| Price | $1.67 | $9.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $1.50 | ★ $25.56 |
| AVG Volume (30 Days) | ★ 6.2M | 2.2M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $3,866,956,000.00 | $67,482,000.00 |
| Revenue This Year | $7.51 | $28.28 |
| Revenue Next Year | $3.46 | $106.37 |
| P/E Ratio | $84.00 | ★ N/A |
| Revenue Growth | 7.46 | ★ 25.24 |
| 52 Week Low | $0.81 | $5.45 |
| 52 Week High | $3.46 | $12.49 |
Technical Indicators
Market Signals| Indicator | SABR | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 46.75 |
| Support Level | $1.49 | $8.80 |
| Resistance Level | $1.70 | $9.82 |
| Average True Range (ATR) | 0.12 | 0.54 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 35.80 | 20.89 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.